Polyanalgesic consensus conference-2012: Recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain

Neuromodulation

Volumn 15, Issue 5, 2012, Pages 467-482

  Deer, Timothy R ^a   Levy, Robert ^b   Prager, Joshua ^c   Buchser, Eric ^d   Burton, Allen ^e   Caraway, David ^f   Cousins, Michael ^g   De Andrés, José ^h   Diwan, Sudhir ⁱ   Erdek, Michael ^j   Grigsby, Eric ^k   Huntoon, Marc ^l   Jacobs, Marilyn S ^c   Kim, Philip ^m,n   Kumar, Krishna ^o   Leong, Michael ^p   Liem, Liong ^q   McDowell, Gladstone C ^r   Panchal, Sunil ^s   Rauck, Richard ^t   Saulino, Michael ^u   Todd Sitzman, B ^v   Staats, Peter ^w,x   Stanton Hicks, Michael ^y   Stearns, Lisa ^z   Wallace, Mark ^aa   Dean Willis, K ^ab,ac   Witt, William ^ad   Yaksh, Tony ^aa   Mekhail, Nagy ^y   more..

^a Center for Pain Relief   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e Houston Pain Associates LLC   (United States)

^f Tri State LLC   (United States)

^g ROYAL NORTH SHORE HOSPITAL   (Australia)

^h UNIVERSITY OF VALENCIA   (Spain)

ⁱ STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k Napa Pain Institute and Neurovations Clinical Research and Education   (United States)

^l VANDERBILT UNIVERSITY   (United States)

^m CHRISTIANA HOSPITAL   (United States)

ⁿ BRYN MAWR HOSPITAL   (United States)

^o UNIVERSITY OF SASKATCHEWAN   (Canada)

^p STANFORD UNIVERSITY   (United States)

^q ST ANTONIUS HOSPITAL   (Netherlands)

^r Integrated Pain Solutions   (United States)

^s National Institute of Pain   (United States)

^t WAKE FOREST SCHOOL OF MEDICINE   (United States)

^u THOMAS JEFFERSON UNIVERSITY   (United States)

^v PLLC   (United States)

^w Premier Pain Management Centers   (United States)

^x JOHNS HOPKINS UNIVERSITY   (United States)

^y LERNER RESEARCH INSTITUTE   (United States)

^z Center for Pain and Supportive Care   (United States)

^aa UNIVERSITY OF CALIFORNIA   (United States)

^ab Alabama Pain Center Huntsville   (United States)

^ac UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^ad UNIVERSITY OF KENTUCKY   (United States)

more..

Author keywords

Chronic pain; consensus; intrathecal; morbidity; mortality; opioids; outcomes

Indexed keywords

ANTIBIOTIC AGENT; BACLOFEN; CREATINE KINASE; HYDROMORPHONE; MORPHINE; MORPHINE SULFATE; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA CONOTOXIN MVIIA; OPIATE; PARACETAMOL; PSEUDOMONIC ACID;

AIRWAY; ANALGESIA; APNEA HYPOPNEA INDEX; ARTICLE; AWARENESS; BACTERIAL MENINGITIS; BRADYPNEA; CANCER PAIN; CATHETER INFECTION; CATHETER OCCLUSION; CENTRAL NERVOUS SYSTEM INFECTION; CHRONIC PAIN; CLINICAL PRACTICE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CREATINE KINASE BLOOD LEVEL; DEVICE INFECTION; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EDUCATION; GENERAL ANESTHESIA; GRANULOMA; HEALTH CARE PERSONNEL; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; INFECTION; INFECTION CONTROL; INTRATHECAL DRUG ADMINISTRATION; INTRATHECAL PUMP; KIDNEY FAILURE; LOCAL ANESTHESIA; LOW DRUG DOSE; MEDICAL ERROR; MENINGITIS; MENTAL DISEASE; MOOD DISORDER; MORBIDITY; MORTALITY; MYELOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL REHYDRATION THERAPY; OXYGEN SATURATION; PAIN; PATIENT CARE; PATIENT MONITORING; PERIPHERAL EDEMA; PHYSICIAN; POSTDURAL PUNCTURE HEADACHE; POSTOPERATIVE PAIN; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PREOPERATIVE PERIOD; PSYCHOSIS; RESPIRATION DEPRESSION; RISK FACTOR; SMOKING CESSATION; SPINAL ANESTHESIA; STAPHYLOCOCCUS INFECTION; SUICIDAL IDEATION; WEIGHT REDUCTION; WOUND CLOSURE; WOUND HEALING; WOUND INFECTION; WOUND IRRIGATION;

ANALGESICS; CHRONIC PAIN; DRUG DELIVERY SYSTEMS; HUMANS; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, SPINAL;

EID: 84867579834     PISSN: 10947159     EISSN: 15251403     Source Type: Journal    
DOI: 10.1111/j.1525-1403.2012.00486.x     Document Type: Article

References (76)

1. Staats PS, Yearwood T, Charapata SG, et al,. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized control trial. JAMA 2004; 291: 63-70.
2. Coffey RJ, Owens ML, Broste SK, et al,. Medical practice perspective: identification and mitigation of risk factors for mortality associated with intrathecal opioids for non-cancer pain. Pain Med 2010; 11: 1001-1009.
3. Coffey RJ, Owens ML, Broste SK, et al,. Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain. Anesthesiology 2009; 111: 881-891.
4. Rathmell JP, Miller MJ,. Death after initiation of intrathecal drug therapy for chronic pain: assessing risk and designing prevention. Anesthesiology 2009; 111: 706-708.
5. US Food and Drug Administration. 2012. Medical Devices. Manufacturer and User Facility Device Experience Database (MAUDE). http://www.fda.gov/ MedicalDevices/DeviceRegulationandGuidance/PostmarketRequirements/ ReportingAdverseEvents/ucm127891.htm
6. Deer T, Krames ES, Hassenbusch SJ, et al,. Polyanalgesic Consensus Conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2007; 10: 300-328.
7. Portenoy RK, Hassenbusch SJ,. Polyanalgesic Consensus Conference 2000. J Pain Symptom Manage 2000; 20: S3.
8. Krames E, Poree L, Deer T, Levy R,. Implementing the SAFE principles for the development of pain medicine therapeutic algorithms that include neuromodulation techniques. Neuromodulation 2009; 12: 104-113.
9. Deer TR,. A critical time for practice change in the treatment continuum: we need to reconsider the role of pumps in the patient care algorithm. Pain Med 2010; 11: 987-989.
10. Deer TR, Smith HS, Cousins M, et al,. Consensus guidelines for the selection and implantation of patients with non-cancer pain for intrathecal drug delivery. Pain Physician 2010; 13: E175-E213.
11. Deer TR, Smith HS, Burton AW, et al,. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physicain 2011; 14: E283-E312.
12. Burton AW, Deer TR, Wallace MS, Rauck RL, Grigsby E,. Considerations and methodology for trialing ziconotide. Pain Physician 2010; 13: 23-33.
13. Henderson JM, Levy RM, Bedder MD, et al,. NANS training requirements for spinal cord stimulation devices: selection, implantation, and follow-up. Neuromodulation 2009; 12. 171-174. doi: 10.1111/j.1525-1403.2009.00211.x.
14. Marien H, Rodenstein D,. Morbid obesity and sleep apnea. Is weight loss the answer? J Clin Sleep Med 2008; 4: 339-340.
15. Urrutia I, Capelastegui A, Quintana JM, et al,. Smoking habit, respiratory symptoms and lung function in young adults. Eur J Public Health 2005; 15: 160-165.
16. Gay PC,. The value of assessing risk of obstructive sleep apnea in surgical patients: it only takes one. Journal of Sleep Medicine 2010; 6: 473-474.
17. Centers for Disease Control. Policy impact: prescription painkiller overdoses. JAMA 2011; 305: 1315-1321.
18. Deer T, Levy RM, Prager J, et al,. Polyanalgesic Consensus Conference. 2012: Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. (in press)
19. Gofeld M, McQueen CK,. Ultrasound-guided intrathecal pump access and prevention of the pocket fill. Pain Med 2011; 12: 607-611.
20. Medtronic. 2011. Urgent: medical device correction. Important clinical information about pocket fills. SynchroMed II and SynchroMed EL Implantable Drug Pumps. http://professional.medtronic.com/wcm/groups/mdtcom-sg/ @mdt/@neuro/documents/documents/hcp-pocket-refill.pdf
21. Medtronic. 2011. News Room. News Release. FDA Classifies Labeling Corrections Related to Occurrence of Pocket Fills during a SynchroMed Implantable Infusion Pump Refill as a Class I Recall. http://wwwp.medtronic.com/ Newsroom/NewsReleaseDetails.do?itemId=1297865182504&format=pdf&lang= en-US (accessed 21 April 2011).
22. US Food and Drug Administration. 2004. Letter of Approval for Prialt (Ziconotide). http://www.accessdata.fda.gov/drugsatfda-does/nda/2004/21-060- Prialt-Approv.PDF
23. Epstein NE,. Preoperative, intraoperative, and postoperative measures to further reduce spinal infections. Surg Neurol Int 2011; 2: 17-22.
24. Dipaola CP, Saravanja DD, Boriani L, et al,. Postoperative Infection Treatment Score for the Spine (PITSS): construction and validation of a predictive model to define need for single versus multiple irrigation and debridement for spinal surgical site infection. Spine J 2012; 12: 218-230. Epub 2012 Mar 3.
25. Dellinger EP, Hausmann S, Bratzler D, et al,. Hospitals collaborate to decrease surgical site infections. American Journal of Surgery 2005; 190: 9-15.
26. Deer T, Stewart CD,. Complications of spinal cord stimulation: identification, treatment, and prevention. Pain Med 2008; 9: S93-S101.
27. Hassenbusch S, Burchiel K, Coffey RJ, et al,. Management of intrathecal catheter-tip inflammatory masses: a consensus statement. Pain Med 2002; 3: 313-323.
28. Yaksh TL, Horais KA, Tozier NA, et al,. Chronically infused intrathecal morphine in dogs. Anesthesiology 2003; 99: 174-187.
29. Deer TR, Caraway DL, Kim CK, Dempsey CD, Stewart CD, McNeil KF,. Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine. Spine J 2002; 2: 274-278.
30. Mironer YG, Haasis JC, Chapple I, Brown C, Satterthwaite JR,. Efficacy and safety of intrathecal opoid/bupivicaine mixture in chronic nonmalignant pain: a double blind, randomized, crossover, multicenter study by the national forum of independent pain clinicians (NFIPC). Neuromodulation 2002; 5: 208-213.
31. Veizi IE, Hayek SM, Narouze S, Pope JE, Mekhail N,. Combination of intrathecal opioids with bupivacaine attenuates opoid dose escalation in chronic noncancer pain patients. Pain Med 2011; 12: 1481-1489.
32. Phillips JA, Escott EJ, Moossy JJ, Kellermier HC,. Imaging of intrathecal catheter tip granulomas: report of three cases and review of the literature. AJR Am J Roentgenol 2007; 189: W375-W381.
33. Leong SK, Laing B, Saines N,. Magnetic resonance imaging (MRI) and computed tomography (CT) findings in intrathecal granuloma: report of two cases. Eur J Radiol Extra 2010; 74: e17-e21.
34. Abs R, Verhelst J, Maeyaert J, et al,. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000; 85: 2215-2222.
35. Katz N,. The impact of opioids on the endocrine system. Clinical Journal of Pain 2009; 25 (2): 170-175.
36. Asensio-Samper JM, De Andrés-Ibáñez J, Fabregat Cid G, Villanueva Pérez V, Alarcõn L,. Ultrasound-guided transversus abdominis plane block for spinal infusion and neurostimulation implantation in two patients with chronic pain. Pain Pract 2010; 10: 158-162.
37. Rauck R, Deer T, Rosen S, et al,. Accuracy and efficacy of intrathecal administration of morphine sulfate for treatment of intractable pain using the Prometra programmable pump. Neuromodulation 2010; 13: 102-108.
38. Atli A, Theodore BR, Turk DC, Loeser JD,. Intrathecal opioid therapy for chronic nonmalignant pain: a retrospective cohort study with 3-year follow-up. Pain Med 2010; 11: 1010-1016.
39. Ver Donck A, Collins R, Rauck RL, Nitescu P,. An open-label, multicenter study of the safety and efficacy of intrathecal ziconotide for severe chronic pain when delivered via an external pump. Neuromodulation 2008; 11: 103-111.
40. Kongkam P, Wagner DL, Sherman S, et al,. Intrathecal narcotic infusion pumps for intractable pain of chronic pancreatitis: a pilot series. Am J Gastroenterol 2009; 104: 1249-1255.
41. Sloan P,. Rapidly escalating intrathecal opioid dosing for cancer pain: a case report of catheter malposition not hyperalgesia. J Pain Symptom Manage 2010; 39: 446-447.
42. Sorokin A, Annabi E, Yang WC, Kaplan R,. Subdural intrathecal catheter placement: experience with two cases. Pain Physician 2008; 11: 677-680.
43. Turner JA, Sears JM, Loeser JD,. Programmable intrathecal opioid delivery systems for chronic noncancer pain: a systematic review of effectiveness and complications. Clin J Pain 2007; 23: 180-195.
44. Mercadante S, Intravaia G, Villari P, et al,. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain 2007; 23: 793-798.
45. Raffaeli W, Righetti D, Caminiti A, et al,. Implantable intrathecal pumps for the treatment of noncancer chronic pain in elderly population: drug dose and clinical efficacy. Neuromodulation 2008; 11: 33-39.
46. Ruan X, Couch JP, Liu H, Shah RV, Wang F, Chiravuri S,. Respiratory failure following delayed intrathecal morphine pump refill: a valuable, but costly lesson. Pain Physician 2010; 13: 337-341.
47. Webster LR, Choi Y, Desai H, Webster L, Grant BJ,. Sleep-disordered breathing and chronic opioid therapy. Pain Med 2008; 9: 425-432.
48. Reig E, Abejon D,. Continuous morphine infusion: a retrospective study of efficacy, safety, and demographic variables. Neuromodulation 2009; 12: 122-129.
49. Ghafoor VL, Epshteyn M, Carlson GH, Terhaar DM, Charry O, Phelps PK,. Intrathecal drug therapy for long-term pain management. Am J Health Syst Pharm 2007; 64: 2447-2461.
50. Ramanathan T,. 2011. Medscape Reference. Drugs, Conditions & Procedures. Aseptic Meningitis. Overview of Aseptic Meningitis. http://emedicine.medscape.com/article/1169489-overview#aw2aab6b2 (accessed 17 May 2011).
51. Pasutharnchat K, Tan KH, Abdul Hadi M, Ho KY,. Intrathecal analgesia in patients with cancer pain-an audit in a tertiary institution. Ann Acad Med Singapore 2009; 38: 943-946.
52. Wallace MS, Rauck R, Fisher R, Charapata SG, Ellis D, Dissanayake S,. Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesth Analg 2008; 106: 628-637. table of contents.
53. Saltari MR, Shaladi A, Piva B, et al,. The management of pain from collapse of osteoporotic vertebrae with continuous intrathecal morphine infusion. Neuromodulation 2007; 10: 167-176.
54. Duarte RV, Raphael JHSJ, Baker C, Hanu-Cernat D,. Intrathecal inflammatory masses: is the yearly opioid dose increase an early indicator? Neuromodulation 2010; 13: 109-112.
55. Cohen SP, Dragovich A,. Intrathecal analgesia. Med Clin North Am 2007; 91: 251-270.
56. Chaudhari M, Machenzi P,. Implantable technology for pain management. Anaesth Intensive Care Med 2008; 9: 69-74.
57. Medtronic. For Healthcare Professionals. Intrathecal Drug Delivery for Chronic Pain. Medical Device Correction-January. 2008. Inflammatory mass (granuloma) at or near the distal tip of intrathecal catheters. http://professional.medtronic.com/wcm/groups/mdtcom-sg/@mdt/@neuro/documents/ documents/inflammatory-mass-letter.pdf (accessed 24 May 2011).
58. Deer T, Prager J, Levy RM, et al,. Polyanalgesic Consensus Conference (PACC). Consensus on diagnosis, detection, and treatment of catheter-tip granulomas (inflammatory masses). Neuromodulation 2012; e-pub ahead of print. DOI: 10.1111/j.1525-1403.2012.00449.x
59. Fitzgibbon D, Posner K, Domino K, Caplan R, Lee L, Cheney F,. Chronic pain management: American Society of Anesthesiologists closed claims project. Anesthesiology 2004; 100: 98-105.
60. Kress HG, Simpson KH, Marchettini P, Ver Donck A, Varrassi G,. Intrathecal therapy: what has changed with the introduction of ziconotide. Pain Pract 2009; 9: 338-347.
61. Thompson JC, Dunbar E, Laye RR,. Treatment challenges and complications with ziconotide monotherapy in established pump patients. Pain Physician 2006; 9: 147-152.
62. Maier C, Gockel HH, Gruhn K, Krumova EK, Edel MA,. Increased risk of suicide under intrathecal ziconotide treatment?-a warning. Pain 2010; 152: 235-237.
63. Schmidtko A, Lötsch J, Freynhagen R, Geisslinger G,. Ziconotide for treatment of severe chronic pain. Lancet 2010; 375: 1569-1577.
64. Kumar K, Kelly M, Pirlot T,. Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy. Surg Neurol 2001; 55: 79-86. discussion 86-78.
65. Hassenbusch SJ, Stanton-Hicks M, Covington EC, Walsh JG, Guthrey DS,. Long-term intraspinal infusions of opioids in the treatment of neuropathic pain. J Pain Symptom Manage 1995; 10: 527-543.
66. Tutak U, Doleys DM,. Intrathecal infusion systems for treatment of chronic low back and leg pain of noncancer origin. South Med J 1996; 89: 295-300.
67. Aldrete JA, Couto da Silva JM,. Leg edema from intrathecal opiate infusions. Eur J Pain 2000; 4: 361-365.
68. Vuong C, Van Uum SH, O'Dell LE, Lutfy K, Friedman TC,. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev 2010; 31: 98-132.
69. Sadiq SA, Poopatana CA,. Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity. J Neurol 2007; 254: 1464-1465.
70. Webster LR, Fakata KL, Charapata S, Fisher R, MineHart M,. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med 2008; 9: 282-290.
71. Gatscher S, Becker R, Uhle E, Bertalanffy H,. Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentiation pain. Acta Neurochir Suppl 2002; 79: 75-76.
72. Ruan X, Tadia R, Couch JP, Ruan J, Chiravuri S,. Severe peripheral edema during an outpatient continuous epidural morphine infusion trial in a patient with failed back surgery syndrome. Pain Physician 2008; 11: 363-367.
73. Azur Pharmaceuticals. Prialt. [package insert]. Philadelphia, PA: Azur Pharma Inc., 2010.
74. Ilias W, le Polain B, Buchser E, Demartini L,. Patient-controlled analgesia in chronic pain patients: experience with a new device designed to be used with implanted programmable pumps. Pain Pract 2008; 8: 164-170.
75. Rainov NG, Buchser E,. Making a case for programmable pumps over fixed rate pumps for the management of fluctuations in chronic pain and spasticity: a literature review. Neuromodulation 2002; 5: 89-99.
76. Buchser E, Durrer A, Chedel D, Mustaki JP,. Efficacy of intrathecal bupivacaine: how important is the flow rate? Pain Med 2004; 5: 248-252.